InvestorsHub Logo
Followers 466
Posts 26938
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 307

Wednesday, 09/11/2013 9:59:38 AM

Wednesday, September 11, 2013 9:59:38 AM

Post# of 350
8:30AM Xenoport announces inclusion of HORIZANT (gabapentin enacarbil) in the WED Foundation Revised Consensus Statement on the Management of RLS/WED (XNPT) 5.89 : Co announced the inclusion of gabapentin enacarbil, the active ingredient in HORIZANT (gabapentin enacarbil) Extended-Release Tablets, as an initial therapy for chronic persistent restless legs syndrome/Willis-Ekbom disease (RLS/WED) in an updated treatment algorithm for patients with RLS/WED. The WED Foundation's algorithm, published in the current issue of Mayo Clinic Proceedings, provides information for physicians determining treatment choices for RLS/WED based on disease severity, existing comorbidities and the long-term benefits and risks of each major class of medications.

The algorithm, first published in 2004, was updated to accommodate several changes in the RLS/WED treatment landscape, including additional knowledge of treatment with nonergot dopamine agonists, increased experience with calcium channel alpha-2-delta ligands and the fact that several long-acting drugs have become available. According to the revised algorithm, either non-ergot dopamine agonists or the calcium channel alpha-2-delta ligands are recommended as initial treatment for patients with chronic persistent RLS/WED, and the choice of the initial treatment should be based on the individual clinical features of RLS/WED in a given patient.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.